Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Keiretsu Forum
Industry: Silicon Valley, California
Anacor Pharmaceuticals (NASDAQ: ANAC)

Organization & Developments: Anacor

Parents

A topical drug that Anacor has been developing for atopic dermatitis—a skin condition commonly called eczema, characterized by chronic, itchy rashes.
Developing a novel chemical class of anti-infective drugs
Eczema drug manufacturer of crisaborole
For use against resistant strains of streptococcus, staphylococcus and other bacterial and fungal human pathogens
Has also entered into a relationship with the U.S. Department of Defense to develop related biodefense agents.
It’s being developed for mild-to-moderate cases of eczema, which is typically treated with steroids.
The drug is an antibody that blocks an enzyme, PDE4, known to play a role in inflammation.
Three lead compounds in development—two of which are topically administered dermatology drugs, while a third is an antibiotic that circulates through the bloodstream to fight Gram-negative bacteria